Similarly, in vitro OX40 engagement by three patient-derived tumour-specific CD4 T-cell lines exhibited heightened cytolytic effects against melanoma cell lines, arguing for in vivo tumoricidal capacity, as observed in the preclinical evaluation (81). The gene discussed is CD4; the disease is neoplasm.